UCB has more than drugs in its 2015 pipeline, while BUPA and biotechs hire new recruits.
Belgian biotech UCB has announced a CEO reshuffle ahead of a wave of product launches.
Jean-Christophe Tellier, currently UCB’s executive VP, Biopharma Brands and Solutions, was appointed CEO-Elect and Chairman of the Executive Committee on March 1.
He will step up to the executive position on January 1, 2015, replacing current CEO Roch Doliveux. The company also plans to appoint Tellier as a member of the Board of Directors at the next AGM on April 24, 2014.
Under Doliveux’s leadership, UCB had evolved from a diversified chemical company into a global biopharmaceutical firm, said Gerhard Mayr, Chairman:
“UCB has surmounted the patent cliff of its former blockbuster products and successfully launched three new core medicines – Cimzia Vimpat and Neupro. We have also accelerated our growth in emerging markets and Japan, while continuously enhancing our R&D productivity to build today’s promising pipeline.”
Doliveux said Tellier will join the company in time for the launch of its pipeline drugs for osteoporosis, lupus and epilepsy, from late 2014 to mid-2016.
Copyright - Unless otherwise stated all contents of this web site are © 2016 - William Reed Business Media SAS - All Rights Reserved - Full details for the use of materials on this site can be found in the Terms & Conditions
The world’s largest modular cGMP biopharmaceutical manufacturing facility came online this week in Wuhan, China.
Valeant, Rentschler, Celgene, MannKind, and Syngene are among those welcoming new leaders for 2016. Oh, and Turing...